Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis
Authors:
- Xiaohu WangXWXiaohu Wang
- Bin MaBMBin Ma
- Kehu YangKYKehu Yang
- Qiuning ZhangQZQiuning Zhang
- Jinhui TianJTJinhui Tian
- 1 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 21 (1) , 120-128
Abstract
The objective of this study was to assess the clinical efficacy and safety of concomitant or adjuvant tomozolomide with whole-brain irradiation (WBI) in patients with brain metastases. MEDLINE, EMBASE, Cochrane Library, Chinese Biomedical Literature Database were searched to identify relevant original published trails, and the references of eligible studies were manually screened. Randomized controlled trails reported in any language, comparing concomitant or adjuvant temozolomide (TMZ) and WBI with WBI alone in patients with brain metastases, were eligible for inclusion. Two investigators independently assessed the quality of included trials and extracted data. The RevMan 5 software was used for statistical analysis. Four trials involving 280 patients were included. The result showed that the group TMZ+WBI was superior to group WBI in partial response, stable disease, progressive disease, and objective response with the pooled risk ratio value and 95% confidence interval, respectively, 1.89 (1.19-3.02), 0.82 (0.45-1.50), 0.29 (0.10-0.78), and 1.72 (1.32-2.24). The incidence of gastrointestinal symptoms and > or =grade 3 myelosuppression presented statistical difference, TMZ+WBI group is higher than WBI group, the pooled risk ratio value and 95% confidence interval were 3.75 (1.04-13.44) and 13 (1.75-96.79), respectively. The currently available evidence showed that the combination of TMZ and WBI may moderately improve the response rate, but accordingly increase the incidence of gastrointestinal symptoms and myelosuppression. Future large-scale, high-quality, placebo-controlled, double-blind trials are needed.Keywords
This publication has 34 references indexed in Scilit:
- Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of LifeBMC Cancer, 2007
- Brain metastasis-Evidence based managementJournal of Cancer Research and Therapeutics, 2006
- Management of Brain Metastases.Current Treatment Options in Neurology, 2004
- Brain metastasesCurrent Neurology and Neuroscience Reports, 2004
- The role of chemotherapy in brain metastasesEuropean Journal of Cancer, 2003
- Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imagingNeuroimaging Clinics Of North America, 2003
- Treatment options for brain metastases in patients with non-small cell lung cancerCurrent Treatment Options in Oncology, 2003
- Front‐line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanomaCancer, 1999
- Primary chemotherapy of brain metastasis in small-cell lung cancer.Journal of Clinical Oncology, 1989
- Distribution of Brain MetastasesArchives of Neurology, 1988